BioMarin announced it will stop dosing certain patients in two mid‑stage trials of Voxzogo following reports of slipped capital femoral epiphysis (SCFE) in independent studies. The company flagged the hip‑related safety concern while the programs continue enrollment and monitoring, and said it is evaluating risk mitigation and further safety assessments. BioMarin did not specify how many patients were affected in the halted cohorts but emphasized patient safety as the reason for the dosing pause. The action underscores heightened regulatory and sponsor scrutiny around orthopedic adverse events for therapies influencing growth and skeletal biology. Source: BioMarin safety notice and industry reporting.